EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

Estelle Baulu iD, Célia Gardet iD, Nicolas Chuvin iD, Stéphane Depil iD

Science Advances · 17.02.2023 · 9 (7)

DOI: 10.1126/sciadv.adf3700 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Advances, erschienen am 17.02.2023. Verfasst von Estelle Baulu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche en Cancérologie de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 463-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell malignancies in hematology. However, their clinical impact on solid tumors has been modest so far. T cells expressing an engineered T cell receptor (TCR-T cells) represent a promising therapeutic alternative. The target repertoire is not limited to membrane proteins, and intrinsic features of TCRs such as high antigen sensitivity and near-to-physiological signaling may improve tumor cell detection and killing while improving T cell persistence. In this review, we present the clinical results obtained with TCR-T cells targeting different tumor antigen families. We detail the different methods that have been developed to identify and optimize a TCR candidate. We also discuss the challenges of TCR-T cell therapies, including toxicity assessment and resistance mechanisms. Last, we share some perspectives and highlight future directions in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasmsHumansReceptors, Antigen, T-CellAntigens, NeoplasmCell- and Tissue-Based Therapy

Substanzen

Receptors, Antigen, T-CellAntigens, Neoplasm

Autor:innen und Institutionen

  • Centre de Recherche en Cancérologie de Lyon, Lyon, France.
  • ErVaccine Technologies, Lyon, France.
  • Centre Léon Bérard, Lyon, France.
  • Université Claude Bernard Lyon 1, Lyon, France.

ORCID-Profile: Estelle Baulu, Célia Gardet, Nicolas Chuvin, Stéphane Depil

Zitieren

APA

Baulu, E., Gardet, C., Chuvin, N., & Depil, S. (2023). TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science Advances, 9(7). https://doi.org/10.1126/sciadv.adf3700

Vancouver

Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Science Advances. 2023;9(7). doi:10.1126/sciadv.adf3700

BibTeX
@article{Baulu2023,
  author = {Baulu, Estelle and Gardet, Célia and Chuvin, Nicolas and Depil, Stéphane},
  title = {TCR-engineered T cell therapy in solid tumors: State of the art and perspectives},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {7},
  doi = {10.1126/sciadv.adf3700}
}
Kostenlos starten →